Who makes Prolonged sedation with isoflurane?

Prolonged sedation with isoflurane is developed by University Hospital, Rouen.

What development phase is Prolonged sedation with isoflurane in?

Prolonged sedation with isoflurane is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

Prolonged sedation with isoflurane

University Hospital, Rouen · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Prolonged sedation with isoflurane
Sponsor	University Hospital, Rouen
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Inhaled Sedation in Critically Ill Patients (PHASE4)
Comparison of Extubation Delay After Prolonged Sedation (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Prolonged sedation with isoflurane CI brief — competitive landscape report
Prolonged sedation with isoflurane updates RSS · CI watch RSS
University Hospital, Rouen portfolio CI